CARLSBAD, Calif., March 2, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $15 million milestone payment from GSK related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
"We are very pleased with the progress we are making with ISIS-TTRRx, and plan to report data from the Phase 2/3 study in 2017. We have many patients who have completed the fifteen months of dosing and are now recei...
- Isis Outperforms 2014 Projections for Pro Forma Net Operating Loss and Year-end Cash
- Isis Achieves Profitable Fourth Quarter
- More than $230 Million in Payments from Partners Drives Significantly Improved Financial Results
- Conference Call Webcast Friday, February 27, 10:30 a.m. ET at www.isispharm.com
CARLSBAD, Calif., Feb. 27, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced it significantly outperformed both its pro forma net operating loss (NOL...
CARLSBAD, Calif., Feb. 24, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE). HAE is a severe and rare genetic disease that is ...
CARLSBAD, Calif., Feb. 20, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
Isis Pharmaceuticals' 2014 Financial Results and Highlights Conference Call
Friday, February 27 at 10:30 a.m. ET / 7:30 a.m. PT
Live on the Internet. Simply log onto our website...
If you are interested in Isis Pharmaceuticals’ investment details, please visit our Investor FAQ page.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Online Investor Kit
Quickly download files right from our Investor Relations Web site.